A Phase 1 interventional study of EDP-938 and Placebo in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-10.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 1, and was the 1st registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Enanta Pharmaceuticals, Inc · Sites in Thailand
Ages 28 days–36 mo
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is close to the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 81 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 1, and was the 1st registered.
Enanta Pharmaceuticals, Inc’s Respiratory Syncytial Virus Infections studies by the year they started, since 2017.
1 of the studies testing EDP-938 in Respiratory Syncytial Virus Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482657Enanta Pharmaceuticals, IncA Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Enanta Pharmaceuticals, Inc’s 14 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects
The first phase assesses single ascending doses for EDP-938 (active drug or placebo) in healthy subjects. A "fasted" and "fed" two-part cohort will also assess food effect.
The second phase assesses multiple ascending doses (active drug or placebo) for 7-days in healthy subjects.
Each cohort within each phase will enroll a total of 8 subjects who will be randomized to receive EDP-938 or placebo. The cohort assessing food effect will enroll 10 subjects randomized to receive EDP-938 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
Drug: EDP-938
EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
Drug: EDP-938
Matching placebo, oral suspension, once daily in one single administration
Drug: Placebo
Matching placebo, oral suspension, once daily for 7 days
Drug: Placebo
Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
placebo to match EDP-938
Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).
Time frame: Up to 8 days
Cmax of EDP-938
Time frame: Up to 5 Days
Cmax of EDP-938
Time frame: Up to 11 Days
AUC of EDP-938
Time frame: Up to 5 Days
AUC of EDP-938
Time frame: Up to 11 Days
Ran from Dec 2017 to primary completion in Jul 2018, 6 months.
Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.
Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-938
Respiratory Syncytial Virus Infections →